Polycystic ovary syndrome (PCOS) is a hormonal disorder characterized by irregular menstrual cycles, excess androgen levels, and polycystic ovaries. It affects 8% to 13% of reproductive-age women, with up to 70% remaining undiagnosed worldwide. The disease contributes to infertility, metabolic complications, and mental health issues, highlighting a significant unmet clinical need for better therapies. Current treatments, such as hormonal contraceptives and insulin sensitizers, often provide limited relief. However, the rising focus on personalized medicine and innovative drug discovery is expected to drive pipeline growth, offering hope for more effective, targeted treatments in the coming years.
The Polycystic Ovary Syndrome Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into polycystic ovary syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for polycystic ovary syndrome. The polycystic ovary syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The polycystic ovary syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with polycystic ovary syndrome treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to polycystic ovary syndrome.
Polycystic ovary syndrome is a hormonal disorder that occurs when there is an imbalance in reproductive hormones, leading to irregular menstrual cycles, ovarian cysts, and elevated androgen levels. This imbalance can cause infertility, metabolic issues, and other symptoms such as excess hair growth and acne.
Treatments for polycystic ovary syndrome aim to manage symptoms. Birth control pills regulate menstrual cycles, while insulin sensitizers address metabolic issues. For fertility, ovulation-inducing medications like clomiphene are used, and treatment is tailored to the individual’s symptoms and needs.
A 2024 systematic review and meta-analysis on the prevalence and accurate diagnosis of polycystic ovary syndrome in adolescents reveals a global prevalence of 9.8%. Regional variations include 2.9% in the Western Pacific to 11.4% in South-East Asia. This epidemiological data highlights the importance of addressing diagnosis accuracy and raising awareness for better management across regions.
This section of the report covers the analysis of polycystic ovary syndrome drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total polycystic ovary syndrome clinical trials.
The drug molecule categories covered under the polycystic ovary syndrome pipeline analysis include small molecules, biologics, peptide-based drugs, and gene- and RNA-based therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for polycystic ovary syndrome.
The EMR polycystic ovary syndrome report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in polycystic ovary syndrome clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for polycystic ovary syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of polycystic ovary syndrome drug candidates.
A Phase 4 study sponsored by Peking University First Hospital aims to evaluate the efficacy of semaglutide in improving metabolic abnormalities and fertility in obese, infertile women with polycystic ovary syndrome (PCOS). The trial includes 75 participants and compares metformin, semaglutide, and their combination alongside lifestyle modifications. The study is expected to conclude by June 2025 and assess weight loss and fertility-related outcomes.
Fujian Shengdi Pharmaceutical Co., Ltd. is sponsoring a Phase 2 multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of HRS9531 injection in obese subjects with polycystic ovary syndrome (PCOS). The study, enrolling 144 participants, began in September 2024 and is expected to be completed by December 2025, addressing critical treatment gaps in PCOS management.
Sponsored by The Foundation for Orthopaedics and Regenerative Medicine, this Phase 1 study aims to evaluate the safety and efficacy of cultured allogeneic adult umbilical cord-derived mesenchymal stem cells (UCDSC) for treating polycystic ovary syndrome (PCOS). The study is expected to be completed by November 2027, with an estimated 20 participants, assessing hormone levels and ultrasound outcomes at 3-, 6-, and 12-months post-treatment.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Polycystic Ovary Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for polycystic ovary syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within polycystic ovary syndrome pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share